PRINCIPAL FINANCIAL GROUP INC - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 163 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.5%.

Quarter-by-quarter ownership
PRINCIPAL FINANCIAL GROUP INC ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$843,708
-35.1%
266,154
+1.7%
0.00%0.0%
Q2 2023$1,300,266
+1.0%
261,623
+0.4%
0.00%0.0%
Q1 2023$1,287,503
-18.4%
260,628
+3.9%
0.00%0.0%
Q4 2022$1,577,903
-41.2%
250,859
+0.9%
0.00%
-50.0%
Q3 2022$2,684,000
-2.4%
248,543
+3.0%
0.00%0.0%
Q2 2022$2,750,000
+27.3%
241,283
+1.7%
0.00%
+100.0%
Q1 2022$2,161,000
-39.2%
237,209
-0.4%
0.00%
-50.0%
Q4 2021$3,553,000
-2.0%
238,117
+68.8%
0.00%0.0%
Q3 2021$3,625,000
-2.1%
141,057
-0.6%
0.00%0.0%
Q2 2021$3,701,000
-24.2%
141,935
+2.6%
0.00%
-33.3%
Q1 2021$4,883,000
+55.3%
138,328
+11.0%
0.00%
+50.0%
Q4 2020$3,145,000
-24.7%
124,602
+12.6%
0.00%
-50.0%
Q3 2020$4,175,000
-9.8%
110,708
+2.4%
0.00%0.0%
Q2 2020$4,629,000
+76.1%
108,097
-20.0%
0.00%
+33.3%
Q1 2020$2,628,000
-24.7%
135,165
+0.6%
0.00%0.0%
Q4 2019$3,492,000
-5.3%
134,413
-0.7%
0.00%0.0%
Q3 2019$3,688,000
+1.6%
135,311
+0.1%
0.00%0.0%
Q2 2019$3,629,000
+114.6%
135,165
+131.1%
0.00%
+50.0%
Q1 2019$1,691,000
-2.4%
58,500
-9.0%
0.00%0.0%
Q4 2018$1,732,00064,3000.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$45,386,0009.32%
TPG Group Holdings (SBS) Advisors, Inc. 18,716,306$472,400,0005.23%
Wildcat Capital Management, LLC 1,515,524$38,252,0004.81%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 900,143$22,720,0003.28%
Coastal Bridge Advisors, LLC 385,824$9,738,0001.93%
Casdin Capital, LLC 945,000$23,852,0000.71%
DSAM Partners (London) Ltd 208,798$5,270,0000.62%
BAINCO INTERNATIONAL INVESTORS 152,839$3,858,0000.44%
Pier Capital, LLC 152,071$3,838,0000.41%
Woodline Partners LP 567,539$14,325,0000.38%
View complete list of ALLOGENE THERAPEUTICS INC shareholders